June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Rescue of transgenic mice expressing human G11778A ND4
Author Affiliations & Notes
  • Hong Yu
    Ophthalmology, Bascom Palmer Eye Inst, Univ of Miami, Miami, FL
  • John Guy
    Ophthalmology, Bascom Palmer Eye Inst, Univ of Miami, Miami, FL
  • Footnotes
    Commercial Relationships Hong Yu, None; John Guy, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hong Yu, John Guy; Rescue of transgenic mice expressing human G11778A ND4. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract 
 
Purpose
 

In our previous work we induced and prevented LHON in mice by sequential injections of two AAV’s, one containing wild-type ND4 and the other mutant human ND4. Development of neutralizing antibodies prevented separation of the double injections by more than a few days, thus we were unable to determine whether wild-type ND4 could improve vision after it was lost. Transgenic mutant ND4 mice have visual loss that begins at 3 months and progresses to blindness 8-11 months after birth. Using transgenic mutant ND4 mice we evaluated whether visual loss can be reversed by intraocular injection of AAV expressing wild-type human ND4.

 
Methods
 

Transgenic mice (n=44) expressing the mutant human NADH ubiquinone oxidoreductase subunit 4 (muthND4) were separated into two groups. The wild-type human ND4 gene with a FLAG epitope tag, under control of the mitochondrial HSP promoter (sc-HSP-ND4FLAG), was packaged with mito-targeted AAV2 (COX8). To intervene quickly after the onset of visual loss, both eyes of mice with low PERG amplitudes were injected with mitochondrially targeted scAAV containing the wild-type (WT) human ND4. Littermates with better vision (higher PERG amplitudes) were injected with sterile PBS.

 
Results
 

To intervene quickly after the onset of visual loss, both eyes of mice with low PERG amplitudes were injected with mitochondrially targeted scAAV containing WT human ND4. Littermates with better vision (higher PERG amplitudes) were injected with sterile PBS. One month later, the amplitudes of wild-type ND4 rescued mice improved compared to their baseline values (p=4.6E-5) (Fig. 1A) and those of littermates injected with PBS (p=0.0005), in whom amplitudes dropped significantly compared to their baseline (p=0.001) (Fig. 1B).

 
Conclusions
 

Visual loss induced by the mutant ND4 in its early stages appears to be rescued by gene therapy with the wild-type allele suggesting hope for acutely blinded LHON patients.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×